Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide add-on therapy in parkinsonian variant multiple system atrophy
2018-004145-16Phase 2Completed
- Sponsor
- Zambon
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing Safinamide 200 mg once daily with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Jun 2019; status: completed.
02
Drugs
safinamide
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2018-004145-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004145-16.